681851-25-2

Usage

Uses

Used in Pharmaceutical Research and Development:
(2R,3S)-2-Methyl-5-oxo-4-(phenylMethyl)-3-Morpholinecarboxylic acid is used as a starting material for the synthesis of various pharmaceuticals and biologically active molecules. Its unique structural properties make it a valuable component in the development of new drugs and therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, (2R,3S)-2-Methyl-5-oxo-4-(phenylMethyl)-3-Morpholinecarboxylic acid serves as a key building block for the creation of complex organic compounds. Its versatility and reactivity contribute to the synthesis of a wide range of chemical products.
Used in Drug Development:
(2R,3S)-2-Methyl-5-oxo-4-(phenylMethyl)-3-Morpholinecarboxylic acid is also studied for its potential medicinal properties in drug development. Its chiral nature and structural features make it a promising candidate for the design and development of innovative pharmaceuticals with specific therapeutic effects.

Upstream product

• 100-52-7 benzaldehyde 
• 94625-13-5 (2S,3R)-2-(benzylamino)-3-hydroxybutanoic acid 
• 79-04-9 chloroacetyl chloride 

Downstream Products

• 681851-26-3 ethyl (2R,3S)-2-methyl-5-oxo-4-(phenylmethyl)morpholine-3-carboxylate 
• 1578155-39-1 (2R,3S)-4-(((R)-6-(2-bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)-2-methylmorpholine-3-carboxylic acid 
• 1571212-59-3 (2R,3S)-4-((6-(2-bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)-2-methylmorpholine-3-carboxylic acid 
• 1571212-69-5 (2R,3S)-2-methylmorpholine-3-carboxylic acid 
• 681851-40-1 (2R,3R)-3-(hydroxymethyl)-2-methylmorpholine hydrochloride 
• 681851-32-1 2,2,2-trichloroethyl (2R,3S)-2-methyl-3-{[(phenylmethyl)sulfanyl]methyl}morpholine-4-carboxylate 
• 681851-30-9 (2R,3S)-2-methyl-4-(phenylmethyl)-3-{[(phenylmethyl)sulfanyl]methyl}morpholine 
• 681851-41-2 (2R,3S)-[2-methyl-4-(phenylmethyl)morpholine-3-yl]methyl methanesulfonate 
• 681851-42-3 (S)-[(2R,3S)-2-methyl-4-(phenylmethyl)morphinan-3-yl] ethanethioate 
• 681851-27-4 (2R,3R)-2-methyl-4-(phenylmethyl)morpholine-3-methanol 
• 681851-34-3 (2R,3S)-2-methyl-3-{[(phenylmethyl)sulfanyl]methyl}morpholine 
• 681851-28-5 (2R,3S)-3-(bromomethyl)-2-methyl-4-(phenylmethyl)morpholine 

Relevant academic research and scientific papers

4 - Methyl dihydro pyrimidine compounds and their use in medicine

The invention relates to a 4-methyl dihydropyrimidine compound and an application thereof as a drug, especially a drug used for treating and preventing hepatitis B, and in particular relates to a compound shown in a general formula (I) or general formula (Ia) in the specification or enantiomers, diastereoisomers, tautomers, hydrates, solvates or pharmaceutically acceptable salts of the compound. All the variables are defined in the specification. The invention also relates to an application of the compound shown in the general formula (I) or general formula (Ia) in the specification or the enantiomers, diastereoisomers, tautomers, hydrates, solvates or pharmaceutically acceptable salts of the compound as drugs, especially drugs used for treating and preventing hepatitis B.

DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS

Provided herein are dihydropyrimidine compounds and their pharmaceutical applications, especially for use in treating and preventing HBV diseases. Specifically, provided herein are compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer,

Synthesis and identification of chiral aminomethylpiperidine carboxamides as inhibitor of collagen induced platelet activation

A series of chiral lactam carboxamides of aminomethylpiperidine were synthesized and investigated for the collagen induced in vitro anti-platelet efficacy and collagen plus epinephrine induced in vivo pulmonary thromboembolism. The compound 31a (30 μM/kg) displayed a remarkable antithrombotic efficacy (60% protection) which was sustained for more than 24 h and points to its excellent bioavailability. The compounds 31a (IC50 = 6.6 μM) and 32a (IC50 = 37 μM), as well as their racemic mixture 28i (IC50 = 16 μM) significantly inhibited collagen-induced human platelet aggregation in vitro. Compound 34c displayed dual mechanism of action against both collagen (IC50 = 3.3 μM) and U46619 (IC50 = 2.7 μM) induced platelet aggregation. The pharmacokinetic study of 31a indicated very faster absorption, prolonged and constant systemic exposure and thereby exhibiting better therapeutic response.

Properties and Reactions of Substituted 1,2-Thiazetidine 1,1-Dioxides: Chiral Mono- and Bicyclic 1,2-Thiazetidine 1,1-Dioxides from α-Amino Acids

New chiral mono- and bicyclic β-sultams, valuable building blocks for drug synthesis, have been prepared from L-Ala, L-Val, L-Leu, L-Ile, L-Phe, L-Cys, L-Ser, L-Thr, and D-penicillamine by transformation of the COOH group into a methylsulfonyl chloride function, followed by cyclization under basic conditions. Selected properties, derivatives, and reactions of the β-sultams are described.